These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 19337422)

  • 1. Tolvaptan and its potential in the treatment of hyponatremia.
    Dixon MB; Lien YH
    Ther Clin Risk Manag; 2008 Dec; 4(6):1149-55. PubMed ID: 19337422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C; Hutchinson DJ
    Clin Ther; 2010 Jun; 32(6):1015-32. PubMed ID: 20637957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AVP receptor antagonists as aquaretics: review and assessment of clinical data.
    Verbalis JG
    Cleve Clin J Med; 2006 Sep; 73 Suppl 3():S24-33. PubMed ID: 16970150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tolvaptan: a vasopressin antagonist for the management of euvolemic and hypervolemic hyponatremia.
    Bulloch MN; Pinner NA
    Expert Rev Clin Pharmacol; 2010 Sep; 3(5):601-12. PubMed ID: 22111741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan, hyponatremia, and heart failure.
    Zmily HD; Daifallah S; Ghali JK
    Int J Nephrol Renovasc Dis; 2011; 4():57-71. PubMed ID: 21694950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vaptans: A new option in the management of hyponatremia.
    Aditya S; Rattan A
    Int J Appl Basic Med Res; 2012 Jul; 2(2):77-83. PubMed ID: 23776817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic potential of vasopressin receptor antagonists.
    Ali F; Guglin M; Vaitkevicius P; Ghali JK
    Drugs; 2007; 67(6):847-58. PubMed ID: 17428103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
    Schrier RW; Gross P; Gheorghiade M; Berl T; Verbalis JG; Czerwiec FS; Orlandi C;
    N Engl J Med; 2006 Nov; 355(20):2099-112. PubMed ID: 17105757
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolvaptan: a new therapeutic agent.
    Aperis G; Alivanis P
    Rev Recent Clin Trials; 2011 May; 6(2):177-88. PubMed ID: 20868352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options for hyponatremia in heart failure.
    Goldsmith SR
    Heart Fail Rev; 2009 Jun; 14(2):65-73. PubMed ID: 18777208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyponatremia in cirrhosis and end-stage liver disease: treatment with the vasopressin V₂-receptor antagonist tolvaptan.
    Gaglio P; Marfo K; Chiodo J
    Dig Dis Sci; 2012 Nov; 57(11):2774-85. PubMed ID: 22732834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaptans for the treatment of hyponatremia.
    Robertson GL
    Nat Rev Endocrinol; 2011 Mar; 7(3):151-61. PubMed ID: 21283124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of tolvaptan in the management of hyponatremia in heart failure patients.
    Nodari S; Jao GT; Chiong JR
    Int J Nephrol Renovasc Dis; 2010; 3():51-60. PubMed ID: 21694929
    [TBL] [Abstract][Full Text] [Related]  

  • 15. V2 receptor antagonist; tolvaptan.
    Yi JH; Shin HJ; Kim HJ
    Electrolyte Blood Press; 2011 Dec; 9(2):50-4. PubMed ID: 22438856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolvaptan for the treatment of hyponatremia and congestive heart failure.
    Ferrer E
    Drugs Today (Barc); 2010 Mar; 46(3):163-71. PubMed ID: 20467590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of tolvaptan treatment between patients with the SIADH and congestive heart failure: a single-center experience.
    Park GH; Lee CM; Song JW; Jung MC; Kim JK; Song YR; Kim HJ; Kim SG
    Korean J Intern Med; 2018 May; 33(3):561-567. PubMed ID: 28286940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of tolvaptan in healthy subjects and patients with hyponatremia secondary to congestive heart failure or hepatic cirrhosis.
    Van Wart SA; Shoaf SE; Mallikaarjun S; Mager DE
    Biopharm Drug Dispos; 2013 Sep; 34(6):336-47. PubMed ID: 23794414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of Tolvaptan's Pharmacokinetic and Pharmacodynamic Properties and Drug Interactions.
    Bhatt PR; McNeely EB; Lin TE; Adams KF; Patterson JH
    J Clin Med; 2014 Nov; 3(4):1276-90. PubMed ID: 26237603
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.